RENAL SAFETY OF PROTON PUMP INHIBITORS

Proton pump inhibitors are a widely used in clinical practice, and are taken by millions of patients around the world for a long time. While proton pump inhibitors are well-tolerated class of drugs, the number of publications has been raised about adverse renal effects, specially their association with acute tubulointerstitial nephritis. It is one of the leading causes of acute renal injury and have catastrophic long-term consequences called chronic kidney disease. In this review, we consider epidemiology, pathogenesis, diagnostic criteria (including biopsy and morphological pattern), clinical manifestations and treatment of proton pump inhibitors-induced acute tubulointerstitial nephritis. A subclinical course without classical manifestations of a cell-mediated hypersensitivity reaction (fever, skin rash, eosinophilia, arthralgia) is characteristic of acute tubulointerstitial nephritis. Increased serum creatinine, decreased glomerular filtration rate, electrolyte disorders, pathological changes in urine tests are not highly specific indicators, but allow to suspect the development of acute tubulointerstitial nephritis. The “gold” standard of diagnosis is the intravital morphological examination of the kidney tissue. Timely diagnosis and immediate discontinuation of the potentially causative drug is the mainstay of therapy and the first necessary step in the early management of suspected or biopsy-proven drug-induced acute tubulointerstitial nephritis. The usage of proton pump inhibitors should be performed only on strict indications with optimal duration of treatment and careful monitoring of kidney function. Multiple comorbidities (older age, heart failure, diabetes, cirrhosis, chronic kidney disease, hypovolemia) increase potential nephrotoxicity. Awareness of this iatrogenic complication will improve diagnosis of proton pump inhibitors-induced acute tubulointerstitial nephritis by multidisciplinary specialists and increase the possibility of successful treatment.

acute tubulointerstitial nephritis, chronic kidney disease, acute renal injury, proton pump inhibitors, creatinine, eosinophils, glomerular filtration rate, glucocorticoids

1. Baker R. Acute tubulointerstitial nephritis: overview. Oxford Textbook of Clinical Nephrology (4 ed.) 2016. Section 4; Chapter 83: 669-677.

2. Geevasinga N., Coleman P.L., Webster A.C., Roger S.D. Proton pump inhibitors and acute interstitial nephritis. ClinGastroenterol Hepatol. 2006; 4(5): 597–604.

3. Kelly C., Neilson E. Tubulointerstitial diseases. Brenner and Rector’s the Kidney edited by Karl Skorecki et al. Elsevier, 10 edition. 2016; Chapter 36: 1209-1230.

4. Krishnan N., Perazella M. Drug-induced acute interstitial nephritis. Kidney Diseases. 2015; 9: 3-13.

5. Leonard Ch. et al. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiology and drug safety. 2012; 21: 1155–11727.

6. U.S. Food and Drug Administration. Proton pump inhibitors: U.S. Food and Drug Administration-approved indications and dosages for use in adults [Internet]. Silver Spring: U.S. Food and Drug Administration; 2014 [cited 2016 Aug 31]. Available from: http:// www.fda.gov/drugs.

7. Scarpignato C., Gatta L., Zullo A., Blandizzi C.; SIF-AIGO-FIMMG Group. Effective and safe proton pump inhibitor therapy in acidrelated diseases. A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016; doi: 10.1186/s12916-0160718-z.

8. Forgacs I., Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008; 336 (7634):2-3.

9. Patterson Burdsall D., Flores H.C., Krueger J., et al. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities. J Am Med Dir Assoc. 2013; 14: 429-432.

10. Wilhelm S.M., Rjater R.G., Kale-Pradhan P.B. Perils and pitfalls of longterm effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013; 6(4): 443-451.

11. Björnsson E., Abrahamsson H., Simrén M. et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a doubleblind, placebo-controlled trial. Aliment Pharmacol. Ther. 2006; 24(6): 945-954.

12. Strand Daniel S., Kim D., Peura D. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut and Liver, Vol. 11, No. 1, January 2017, pp. 27-37.

13. Akram F. et al. Proton pump inhibitors: Are we still prescribing them without valid indications? A.M.J. 2014; 7(11): 465–470.

14. Eusebi L. PROTON PUMP INHIBITORS: RISKS OF LONG-TERM USE. doi: 10.1111/jgh.13737

15. Simpson I.J.M.M., Pilmore H., Manley P., Williams L., Thein H., Voss D. Proton Pump Inhibitor and acute interstitial nephritis: report and analysis of 15 cases. Nephrology. 2006; 11: 381–385.

16. Izzedine H., Guetin V. Drug-induced acute tubulointerstitial nephritis. Oxford Textbook of Clinical Nephrology (4 ed.) Section 4. Chapter 84: 679-686.

17. Moledina D.G., Perazella M.A. PPIs and kidney disease: from AIN to CKD. J. Nephrol. 2016; 29: 611-616.

18. Geevasinga N., Coleman P.L., Webster A.C., Roger S.D. Proton pump inhibitors and acute interstitial nephritis. Clin. Gastroenterol. Hepatol. 2006; 4(5): 597–604.

19. Sierra M. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment. Pharmacol. Ther. 2007; 26: 545-553.

20. Arora P. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. Arora et al. BMC Nephrology. 2016; 17: 112.

21. Lazarus B., Chen Y., Wilson F.P., et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern. Med. 2016; 176: 238-46.

22. Coca S. et al. Chronic Kidney Disease after Acute Kidney Injury: A Systematic Review and Meta-analysis. Kidney Int. 2012 March; 81(5): 442–448. doi:10.1038/ki.2011.379

23. Ruffenach S.J., Siskind M.S., Lien Y.H. Acute interstitial nephritis due to omeprazole. Am. J. Med.1992; 93(4): 472–473.

24. Klepser Donald G., Collier Dean S., Cochran Gary L. Proton pump inhibitors and acute kidney injury: a nested case–control study. BMC Nephrology. 2013; 14: 150.

25. Blank M.L., Parkin L., Paul C., Herbison P. A nationwide nested casecontrol study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014; 86: 837-44.

26. Antoniou T., Macdonald E.M., Hollands S. et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a populationbased cohort study. CMAJ Open. 2015; 3: E166-71.

27. Rossert J., Fischer E. Acute interstitial nephritis. In: Johnson R.J., Feehally J., eds. Comprehensive clinical nephrology. St. Louis, Mosby, 2000:62.1–62.9.

28. Perazella M., Markowitz G. Drug-induced acute interstitial nephritis. Nat. Rev. Nephrol. 2010; 6(8): 461-470.

29. Neilson E.G. Pathogenesis and therapy of interstitial nephritis. Kidney Int. 1989; 35:1257.

30. Chang C., Gershwin M.E. Drugs and autoimmunity-a contemporary review and mechanistic approach. J. Autoimmun. 2010; 34: J266-75.

31. Brodsky S., Nadashy T. Acute and chronic tubulointerstitial nephritis. Heptinstall’s Pathology of the Kidney. Ch. 25: 1111-1165.

32. Baker R.J., Pusey C.D. The changing profile of acute tubulointerstitial nephritis. Nephrol. Dial. Transplant. 2004; 19: 8-11.

33. McCluskey R.T., Colvin R.B. Immunologic aspects of renal tubular and interstitial diseases. Annu Rev. Med. 1978; 29: 191-203.

34. Kurts C. Dendiritic cells: not just another cell type in the kidney, but a complex immune sentinel network. Kidney Int. 2006; 70: 412-414.

35. Rees A. Cross dendritic cells anger T cells after kidney injury. J. A.M. Soc. Nephrol. 2009; 20: 3-5.

36. Dong X., Swaminathan S., Bachman L.A., Croatt A.J., Nath K.A., Griyn M.D. Antigen presentation by dendritic cells in renal lymph nodes is linked to systemic and local injury to the kidney. Kidney Int. 2005; 68: 1096-1108.

37. Soos T.J., Sims T.N., Barisoni L., et al. CX3CR1+ interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int. 2006; 70: 591-596.

38. Rogers N.M., Ferenbach D.A., Isenberg J.S., Thomson A.W., Hughes J.D. Dendritic cells and macrophages in the kidney: a spectrum of good and evil. Nat. Rev. Nephrol. 2014; 10: 625-643.

39. Segerer S., Nelson P.J., Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J. Am. Soc. Nephrol. 2000; 11: 152-76.

40. Kasiske B.L., Keane W.F. Laboratory assesment of renal biopsy. Brenner and Rector’s the Kidney edited by Karl Skorecki et al. Elsevier, 10 edition. 2016: 1137-1174.

41. Walker P. The renal biopsy. Arch.Pathol.Lab.Med. 2009. 133:181-188.

42. Батюшкин М.М. Роль анальгетиков и нестероидных противовоспалительных препаратов в развитии интерстициального поражения почек. Нефрология и диализ. 2008; 8(3): 239-243. Batiushkin, M.M. The role of analgesics and non-steroidal antiinflammatory drugs in the development of interstitial kidney damage. Nephrology and dialysis. 2008; 8(3): 239-243 [in Russian].

43. Пентюк О.О. Нефротоксичність лікарських засобів: клінічні прояви, патофізіологічні механізми та підходи до лікування. Раціон.фармакотерапія. 2009; 1: 21-27. Pentiuk O.O. Nephrotoxicity of drugs: clinical manifestations, pathophysiological mechanisms and approaches to treatment. Ration. Pharmacotherapy. 2009; 1: 21-27 [in Russian].

44. Clarcson M., Gibilin L. et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol. Dial. Transplant. 2004; 19: 2778-2783.

45. Blowey D.L. Nephrotoxicity of over-the-counter analgesics, natural medicines and illicit drugs. Adolesc. Med. 2005; 16: 31-43.

46. Команденко М.С. Шостка Г.Д. Гиперчувствительный тубулоинтерстициальный нефрит (ТИН) в Санкт-Петербурге. Нефрология и диализ. 2001; 3(2): 144-145 Komandenko M.S., Shostka G.D. Hypersensitive tubulointerstitial nephritis (TIN) in St. Petersburg. Nephrology and dialysis. 2001; 3 (2): 144-145 [in Russian].

47. Мамедова Л.Н., Тарасова Г.Н. Оптимальный выбор ингибитора протонной помпы при хронической болезни почек. Фарматека. 2015; 15: 57-63. Mamedova LN, Tarasova GN Optimal choice of a proton pump inhibitor in chronic kidney disease. Pharmatec. 2015; 15: 57-63 [in Russian].

48. Saran et al. US Renal data system 2016 Annual data report Epidemiology of Kidney disease in the United States. Am. J. Kidney Dis. 2017. 69 (3): 1-2.

49. Yang Y., Geoge K. et al. Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies. Drug Design, Development and Therapy. 2017; 11: 1291–1299.

50. Lazarus B., Chen Y., Wilson F.P., et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern. Med. 2016; 176: 238-46.

51. Xie Y. et al. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney International. 2017; E-pub: 1-13. doi: 10.1016/j.kint.2016.12.021

52. Toth-Manikowski M.S., Grams M.E. Proton Pump Inhibitors and Kidney Disease—GI Upset for the Nephrologist? Kidney International Reports. 2017; 2: 297–301.

53. Сигитова О.Н., Архипов Е.В. Тубулоинтерстициальный нефрит. Вестник современной клинической медицины. 2010. 3(3): 45-49 Sigitova O.N., Arkhipov E.V. Tubulointerstitial nephritis. Herald of modern clinical medicine. 2010; 3(3): 45-49[in Russian].

54. Clarcson M.R. et al. Acute iterstitial nephritis% clinical features and response to corticosteroid therapy. Nephrol. Dial. Transplant. 2004; 19(11): 2778-2783.

55. Praga M., Gonzales E. Acute interstitial nephritis. Kidney Int. 2010; 77(11): 956-61.

56. Gonzales E. Gutierrez E., Galeano C. et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008; 73(8): 940-946.

57. Muriithi A.K., Leung N., Valeri A.M., et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am. J. Kidney Dis. 2014; 64: 558-566.